Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 1
A Phase I Study of ATRN-119, an ATR Inhibitor, in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
This is a single-center, open-label, phase I study with dose escalation and dose expansion testing the combination of ATRN-119 and decitabine in patients with …
Acute Myeloid LeukemiaHigh-risk Myelodysplastic Syndrome
Estimated
~$10 – $6,250
Washington University School of MedicineNCT07617363
Phase 1
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of …
Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaHigh-risk Myelodysplastic Syndrome
Estimated
~$10 – $8,750
Vincerx Pharma, Inc.NCT06034275
Phase 1
CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants …
High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)AML - Acute Myeloid Leukemia+1 more
Estimated
~$10 – $8,750
Crossbow Therapeutics, Inc.NCT06994676